RARA and melanoma: In the univariate analysis, expressions of cluster of differentiation (CD) 34, CD56, CD64 and CD2, PML‐RARA type, co‐expression of FLT3‐ITD, complex karyotype, Wilms tumour 1 (WT1), preferentially expressed antigen in melanoma (PRAME), and leukocytosis during induction therapy were not associated with relapse (Table 3).